Testing a CAR T immune cell therapy, BCB-276, for children and young adults with DIPG
Official title: Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing an immune cell therapy for DIPG, given after radiation.
Read our full plain-language summary
What the trial team says
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG. To participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for treatment within 6 weeks of completing initial radiation therapy. Participants must not have received prior anti-cancer therapy beyond radiation with or without temozolomide prior to joining this study. BCB-276 is administered intraventricularly (into the fluid around the brain), which requires placement of a catheter for treatment. BCB-276 is given every 2 weeks at a research center over a period of several months (approximately 7-8 months). Participation includes travel to a study site, procedures to support treatment administration, sample collection, and ongoing monitoring for safety and effectiveness, with follow-up visits lasting up to about 2 years.
Key facts
- Registry number
- NCT07680439
- Stage of testing
- Phase 2
- Conditions studied
- Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
Where it is running
This trial lists 6 sites.
-
California
- Children's Hospital Los Angeles (Los Angeles)
-
Georgia
- Children's Healthcare of Atlanta (Atlanta)
-
Illinois
- Lurie Children's Hospital (Chicago)
-
Ohio
- Nationwide Children's Hospital (Columbus)
-
Pennsylvania
- Children's Hospital of Philadelphia (Philadelphia)
-
Washington
- Seattle Children's Hospital (Seattle)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.